Search for Clinical Trial Results

Sponsored By

Scleroderma, Diffuse - 12 Studies Found

Status Study
Completed Study Name: Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2010-07-01
Interventions: Drug: Nilotinib (Tasigna) Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
Active, not recruiting Study Name: Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Date: 2015-05-22
Interventions:
  • Other: Internet-based self-management program
Completed Study Name: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2007-11-07
Interventions: Drug: Imatinib Mesylate In initial phase, patients will be treated with Gleevec 400 mg daily for 12 mont
Completed Study Name: Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2008-04-25
Recruiting Study Name: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Condition: Scleroderma
Date: 2012-06-18
Interventions: Drug: Campath Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the incl
Completed Study Name: Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Date: 2008-04-23
Completed Study Name: A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Condition:
  • Scleroderma, Diffuse
  • Scleroderma,
    Date: 2007-03-01
    Interventions:
    • Drug: Abatacept Active drug, a
Completed Study Name: Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Condition: Scleroderma, Systemic
Date: 2006-06-02
Interventions: Drug: Mycophenolate mofetil
Recruiting Study Name: Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
Condition: Scleroderma
Date: 2011-09-29
Interventions:
  • Procedure: Cytoxan rATG/Fludarabine/HSCT

Completed Study Name: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Condition: Systemic Scleroderma
Date: 2015-01-18
Interventions:
  • Drug: C-82 Topical Gel, 1% act
Next >>>